The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Beta‐lactamase inhibitor enhances Helicobacter pylori eradication rate
Abstract
OBJECTIVES: One-week triple therapy, a combination of acid suppression with two antibiotics, is the gold standard for anti-Helicobacter pylori treatment. There is increasing evidence of H. pylori resistance to classical triple therapy. Recently, it was reported that the amoxicillin-clavulanate combination had a slightly higher activity than amoxicillin alone against H. pylori, and that beta-lactamase inhibitors had 'in-vitro' antibacterial activity against H. pylori. SETTING: To evaluate the efficacy of 1 week triple therapy omeprazole, clarithromycin and amoxicillin plus clavulanate compared with omeprazole, clarithromycin and amoxicillin for H. pylori eradication. The study was open randomized. SUBJECTS: Sixty dyspeptic patients (36 male, 24 female; mean age 53 +/- 9 years) with Helicobacter pylori infection never treated before, were enrolled and randomly assigned to two different 7-day triple therapies: (i) (n = 30) amoxicillin 875 mg plus clavulanic acid 125 mg b.i.d., clarithromycin 500 mg b.i.d., omeprazole 20 mg b.i.d. (ACCO); (ii) (n = 30) amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d., omeprazole 20 mg b.i.d. (ACO). Bacterial eradication was assessed by 13C-urea breath test 4-6 weeks after therapy. Information on gastrointestinal symptoms and antibiotic-related side-effects were recorded using a questionnaire. RESULTS: All patients completed the study. A significantly higher H. pylori eradication rate with ACCO compared with ACO: (26/30) 86.6 vs. (20/30) 66.6%, respectively (P < 0.05) were observed. No major side-effects were reported, whilst 8% patients complained of mild side-effects; no significant differences were noted between the two groups. CONCLUSIONS: Our results suggest that amoxicillin and clavulanate in combination achieve a higher H. pylori eradication rate than amoxicillin alone, without any increase in side-effects. The combination of amoxicillin and clavulanate may represent an alternative therapeutic scheme for the treatment of H. pylori infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A randomized clinical trial by Ojetti et al. demonstrated significantly higher eradication rates with an amoxicillin-clavulanate-containing triple regimen compared with amoxicillin alone, without an increase in adverse effects.”
From Clinical Outcomes and Real-World Effectiveness of Amoxicillin-Clavulanic Acid Across Indian Healthcare Settings: A Retrospective Multicenter Study (2026) · cites this paper as [20]
Citations
Cites
Malfertheiner, P., Mégraud, F., O'Morain, C. A., Hungin, A. P. S., Jones, R. H., Axon, A. T. R., Graham, D. Y., Tytgat, G. N. J., & The European Helicobacter Pylori Study Group (EHPSG) (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01169.x · Cited by 1,238
Malfertheiner, P., Mégraud, F., O'Morain, C. A., Bell, D. A., Porro, B. G., Deltenre, M. A. L., Forman, D., Gasbarrini, G., Jaup, B. H., Misiewicz, J. J., et al. (1997) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199701000-00002 · Cited by 979
Self-citationBMJ Publishing Group Ltd and British Society of Gastroenterology (1997) · Gut · doi:10.1136/gut.41.1.8 · Cited by 787
Epidemiology and Diagnosis of H elicobacter pylori infection
Mentis, A. F., Lehours, P., & Mégraud, F. (2015) · Helicobacter · doi:10.1111/hel.12250 · Cited by 396
Cremonini, F., Caro, S., Covino, M., Armuzzi, A., Gabrielli, M., Santarelli, L., Nista, E. C., Cammarota, G., Gasbarrini, G., & Gasbarrini, A. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.07063.x · Cited by 341
Self-citationHouben, van de Beek, D., Hensen, de Craen, A. J. M., Rauws, & Tytgat (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00555.x · Cited by 330
Antibiotic resistance in : Implications for therapy
Graham, D. Y. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70100-3 · Cited by 300
The proton-pump inhibitors: Similarities and differences
Horn, J. R. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80032-6 · Cited by 244
Cammarota, G., Cianci, R., Cannizzaro, O., et al. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00846.x · Cited by 160
Extradigestive manifestations of Helicobacter pylori gastric infection
Gasbarrini, A., Franceschi, F., Armuzzi, A., Ojetti, V., Candelli, M., Torre, E. S., LORENZO, A. D., Anti, M., Pretolani, S., & Gasbarrini, A. (1999) · Gut · doi:10.1136/gut.45.2008.i9 · Cited by 134
Self-citation
Cited by
Sorted by citations
Chen, M.-C., Lei, W.-Y., Lin, J.-S., Yi, C.-H., Wu, D.-C., & Hu, C.-T. (2014) · BioMed Research International · doi:10.1155/2014/158520 · Cited by 21
Raju, A., Kakar, A., Bhagat, D. K., Behera, S. K., Pathak, R., & Pal, S. (2026) · Cureus · doi:10.7759/cureus.104282
“[20] Additional support for this approach comes from contemporary expert guidance.”
Metadata
- Authors
- Ojetti, V., Migneco, A., Zocco, M. A., Nista, E. C., Gasbarrini, G., & Gasbarrini, A.
- Affiliations
- Agostino Gemelli University Polyclinic (IT)
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2003-12-18
- Volume
- 255
- Issue
- 1
- Pages
- 125-129
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W1997839897
- Cited by
- 21
- References
- 37
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2018: 1 · 2014: 1 · 2013: 1
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Helicobacter pylori, triple therapy, beta-lactamase inhibitors, clavulanic acid, amoxicillin, clarithromycin, omeprazole, Helicobacter pylori eradication, dyspepsia, antibiotic resistance, 13C-urea breath test
- MeSH terms
- beta-Lactamases, Drug Therapy, Combination, Dyspepsia, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Omeprazole, Patient Compliance, Helicobacter pylori, Helicobacter Infections, Clarithromycin, Amoxicillin-Potassium Clavulanate Combination, beta-Lactamase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
